Sotera Health (NASDAQ:SHC) Issues FY24 Earnings Guidance

Sotera Health (NASDAQ:SHC) issued an update on its FY24 earnings guidance on Tuesday morning. The company provided earnings per share (EPS) guidance of $0.67-0.75 for the period, compared to the consensus estimate of $0.72. The company issued revenue guidance of $1.09-1.11 billion, compared to the consensus revenue estimate of $1.11 billion. Sotera Health also updated its FY 2024 guidance to 0.670-0.750 EPS.

Analyst Upgrades and Downgrades

A number of brokerages recently weighed in on SHC. Royal Bank of Canada reissued an “outperform” rating and issued a $17.00 price objective on shares of Sotera Health in a research note on Tuesday, August 6th. Citigroup increased their price objective on Sotera Health from $18.00 to $20.00 and gave the company a “buy” rating in a research report on Wednesday. Finally, Barclays boosted their target price on shares of Sotera Health from $14.00 to $17.00 and gave the stock an “overweight” rating in a research report on Tuesday, August 6th. Two research analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $16.50.

Sotera Health Price Performance

Shares of SHC stock traded down $0.28 during mid-day trading on Thursday, reaching $15.83. The company’s stock had a trading volume of 1,349,204 shares, compared to its average volume of 1,307,183. The company has a market cap of $4.48 billion, a P/E ratio of 63.40 and a beta of 2.08. The company has a debt-to-equity ratio of 5.46, a quick ratio of 2.59 and a current ratio of 2.93. Sotera Health has a 1-year low of $10.71 and a 1-year high of $17.44. The firm’s 50-day moving average is $15.96 and its two-hundred day moving average is $13.69.

Sotera Health (NASDAQ:SHC) last issued its earnings results on Tuesday, November 5th. The company reported $0.17 EPS for the quarter, missing the consensus estimate of $0.18 by ($0.01). Sotera Health had a net margin of 3.65% and a return on equity of 47.26%. The firm had revenue of $285.47 million during the quarter, compared to analyst estimates of $278.64 million. During the same quarter in the prior year, the firm posted $0.18 EPS. The firm’s revenue for the quarter was up 8.5% on a year-over-year basis. On average, research analysts predict that Sotera Health will post 0.64 earnings per share for the current year.

Insider Activity

In other Sotera Health news, Director Gtcr Investment Xi Llc sold 10,000,000 shares of Sotera Health stock in a transaction on Friday, September 6th. The stock was sold at an average price of $15.03, for a total value of $150,300,000.00. Following the completion of the transaction, the director now owns 49,215,301 shares in the company, valued at approximately $739,705,974.03. The trade was a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 55.12% of the stock is currently owned by corporate insiders.

Sotera Health Company Profile

Sotera Health Company engages in the provision of sterilization, lab testing, and advisory services in the United States and internationally. The company operates through three segments: Sterigenics, Nordion, and Nelson Labs. It provides mission-critical end-to-end sterilization services, including gamma and electron beam irradiation, and ethylene oxide processing, as well as designs, installs, and maintains gamma irradiation systems.